Intra-Articular Knee Implantation of Autologous Bone Marrow–Derived Mesenchymal Stromal Cells in Rheumatoid Arthritis Patients With Knee Involvement: Results of a Randomized, Triple-Blind, Placebo-Controlled Phase 1/2 Clinical Trial Publisher Pubmed



Shadmanfar S¹ ; Labibzadeh N² ; Emadedin M² ; Jaroughi N² ; Azimian V² ; Mardpour S² ; Kakroodi FA² ; Bolurieh T² ; Hosseini SE² ; Chehrazi M³ ; Niknejadi M⁴ ; Baharvand H² ; Gharibdoost F⁵ ; Aghdami N² Show Affiliations
Source: Cytotherapy Published:2018

Abstract

Background: In this study, we intend to assess the safety and tolerability of intra-articular knee implantation of autologous bone marrow–derived mesenchymal stromal cells (MSCs) in patients with rheumatoid arthritis (RA) and to determine the preliminary clinical efficacy data in this population. The trial registration numbers are as follows: Royan Institute Ethics Committee: AC/91/1133; NCT01873625. Methods: This single-center, randomized, triple-blind, placebo-controlled phase 1/2 clinical trial randomized RA patients with knee involvement to receive either an intra-articular knee implantation of 40 million autologous bone marrow–derived MSCs per joint or normal saline (placebo). Patients were followed up for 12 months to assess therapy outcomes. Results: A total of 30 patients, 15 in the MSC group and 15 in the placebo group, enrolled in this study. There were no adverse effects reported after MSC administration or during follow-up. Patients who received MSCs had superior findings according to the Western Ontario and McMaster Universities Arthritis Index (WOMAC), visual analogue scale (VAS), time to jelling and pain-free walking distance. However, this improvement could not be significantly sustained beyond 12 months. The MSC group exhibited improved standing time (P = 0.01). In addition, the MSCs appeared to contribute to reductions in methotrexate and prednisolone use. Conclusion: Intra-articular knee implantation of MSCs appeared to be safe and well tolerated. In addition, we observed a trend toward clinical efficacy. These results, in our opinion, have justified the need for further investigations over an extended assessment period with larger numbers of RA patients who have knee involvement. © 2018